Effective on June 30, 2025, China's National Healthcare Security Administration and National Health Commission introduced measures to integrate innovative drugs into the national medical insurance system.
The reform uses the unified medical insurance platform to guide R&D priorities, supports tailoring BMI coverage for innovative drugs, and establishes a Commercial Medical Insurance Innovative Drug List. These initiatives aim to improve innovation efficiency and better align healthcare financing with drug development.